Skip to Content

Bilastine Approval Status

  • FDA approved: No
  • Generic name: Bilastine
  • Company: Inspire Pharmaceuticals, Inc.
  • Treatment for: Allergic Rhinitis

Bilastine is an investigational selective histamine H1 receptor antagonist for the treatment of allergic rhinitis.

In January 2008, Inspire Pharmaceuticals, Inc. announced the termination of the licensing agreement with FAES Farma, S.A. and the cessation of the development and commercialization of bilastine.

Development Status and FDA Approval Process for Bilastine

Jan 14, 2008Inspire Announces Its Termination of Bilastine Licensing Agreement
Jun 20, 2007Inspire and FAES Farma Amend Bilastine Licensing Agreement

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.